<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">34830414</PMID><DateCompleted><Year>2021</Year><Month>12</Month><Day>21</Day></DateCompleted><DateRevised><Year>2021</Year><Month>12</Month><Day>21</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1422-0067</ISSN><JournalIssue CitedMedium="Internet"><Volume>22</Volume><Issue>22</Issue><PubDate><Year>2021</Year><Month>Nov</Month><Day>20</Day></PubDate></JournalIssue><Title>International journal of molecular sciences</Title><ISOAbbreviation>Int J Mol Sci</ISOAbbreviation></Journal><ArticleTitle>BiP Heterozigosity Aggravates Pathological Deterioration in Experimental Amyotrophic Lateral Sclerosis.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">12533</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/ijms222212533</ELocationID><Abstract><AbstractText>In the present study, we investigated the involvement of the chaperone protein BiP (also known as GRP78 or Hspa5), a master regulator of intracellular proteostasis, in two mouse models of neurodegenerative diseases: amyotrophic lateral sclerosis (ALS) and Parkinson's disease (PD). To this end, we used mice bearing partial genetic deletion of the BiP gene (BiP<sup>+/-</sup> mice), which, for the ALS model, were crossed with mutant SOD1 (mSOD1) transgenic mice to generate mSOD1/BiP<sup>+/-</sup> double mutant mice. Our data revealed a more intense neurological decline in the double mutants, reflected in a greater deterioration of the neurological score and rotarod performance, with also a reduced animal survival, compared to mSOD1 transgenic mice. Such worsening was associated with higher microglial (labelled with Iba-1 immunostaining) and, to a lesser extent, astroglial (labelled with GFAP immunostaining) immunoreactivities found in the double mutants, but not with a higher loss of spinal motor neurons (labelled with Nissl staining) in the spinal cord. The morphological analysis of Iba-1 and GFAP-positive cells revealed a higher presence of activated cells, characterized by elevated cell body size and shorter processes, in double mutants compared to mSOD1 mice with normal BiP expression. In the case of the PD model, BiP<sup>+/-</sup> mice were unilaterally lesioned with the parkinsonian neurotoxin 6-hydroxydopamine (6-OHDA). In this case, however, we did not detect a greater susceptibility to damage in mutant mice, as the motor defects caused by 6-OHDA in the pole test and the cylinder rearing test, as well as the losses in tyrosine hydroxylase-containing neurons and the elevated glial reactivity (labelled with CD68 and GFAP immunostaining) detected in the substantia nigra were of similar magnitude in BiP<sup>+/-</sup> mice compared with wildtype animals. Therefore, our findings support the view that a dysregulation of the protein BiP may contribute to ALS pathogenesis. As BiP has been recently related to cannabinoid type-1 (CB<sub>1</sub>) receptor function, our work also opens the door to future studies on a possible link between BiP and the neuroprotective effects of cannabinoids that have been widely reported in this neuropathological context. In support of this possibility, preliminary data indicate that CB<sub>1</sub> receptor levels are significantly reduced in mSOD1 mice having partial deletion of BiP gene.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>G&#xf3;mez-Almer&#xed;a</LastName><ForeName>Marta</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Instituto Universitario de Investigaci&#xf3;n en Neuroqu&#xed;mica, Departamento de Bioqu&#xed;mica y Biolog&#xed;a Molecular, Facultad de Medicina, Universidad Complutense, 28040 Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red de Enfermedades Neurodegenerativas (CIBERNED), 28040 Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Instituto Ram&#xf3;n y Cajal de Investigaci&#xf3;n Sanitaria (IRYCIS), 28040 Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Burgaz</LastName><ForeName>Sonia</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Instituto Universitario de Investigaci&#xf3;n en Neuroqu&#xed;mica, Departamento de Bioqu&#xed;mica y Biolog&#xed;a Molecular, Facultad de Medicina, Universidad Complutense, 28040 Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red de Enfermedades Neurodegenerativas (CIBERNED), 28040 Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Instituto Ram&#xf3;n y Cajal de Investigaci&#xf3;n Sanitaria (IRYCIS), 28040 Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Costas-Insua</LastName><ForeName>Carlos</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0003-3446-6899</Identifier><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red de Enfermedades Neurodegenerativas (CIBERNED), 28040 Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Instituto Ram&#xf3;n y Cajal de Investigaci&#xf3;n Sanitaria (IRYCIS), 28040 Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Instituto Universitario de Investigaci&#xf3;n en Neuroqu&#xed;mica, Departamento de Bioqu&#xed;mica y Biolog&#xed;a Molecular, Facultad de Biolog&#xed;a, Universidad Complutense, 28040 Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rodr&#xed;guez-Cueto</LastName><ForeName>Carmen</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Instituto Universitario de Investigaci&#xf3;n en Neuroqu&#xed;mica, Departamento de Bioqu&#xed;mica y Biolog&#xed;a Molecular, Facultad de Medicina, Universidad Complutense, 28040 Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red de Enfermedades Neurodegenerativas (CIBERNED), 28040 Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Instituto Ram&#xf3;n y Cajal de Investigaci&#xf3;n Sanitaria (IRYCIS), 28040 Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Santos-Garc&#xed;a</LastName><ForeName>Irene</ForeName><Initials>I</Initials><Identifier Source="ORCID">0000-0002-6266-9530</Identifier><AffiliationInfo><Affiliation>Instituto Universitario de Investigaci&#xf3;n en Neuroqu&#xed;mica, Departamento de Bioqu&#xed;mica y Biolog&#xed;a Molecular, Facultad de Medicina, Universidad Complutense, 28040 Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red de Enfermedades Neurodegenerativas (CIBERNED), 28040 Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Instituto Ram&#xf3;n y Cajal de Investigaci&#xf3;n Sanitaria (IRYCIS), 28040 Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rodr&#xed;guez-Crespo</LastName><ForeName>Ignacio</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red de Enfermedades Neurodegenerativas (CIBERNED), 28040 Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Instituto Ram&#xf3;n y Cajal de Investigaci&#xf3;n Sanitaria (IRYCIS), 28040 Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Instituto Universitario de Investigaci&#xf3;n en Neuroqu&#xed;mica, Departamento de Bioqu&#xed;mica y Biolog&#xed;a Molecular, Facultad de Biolog&#xed;a, Universidad Complutense, 28040 Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garc&#xed;a</LastName><ForeName>Concepci&#xf3;n</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Instituto Universitario de Investigaci&#xf3;n en Neuroqu&#xed;mica, Departamento de Bioqu&#xed;mica y Biolog&#xed;a Molecular, Facultad de Medicina, Universidad Complutense, 28040 Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red de Enfermedades Neurodegenerativas (CIBERNED), 28040 Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Instituto Ram&#xf3;n y Cajal de Investigaci&#xf3;n Sanitaria (IRYCIS), 28040 Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guzm&#xe1;n</LastName><ForeName>Manuel</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red de Enfermedades Neurodegenerativas (CIBERNED), 28040 Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Instituto Ram&#xf3;n y Cajal de Investigaci&#xf3;n Sanitaria (IRYCIS), 28040 Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Instituto Universitario de Investigaci&#xf3;n en Neuroqu&#xed;mica, Departamento de Bioqu&#xed;mica y Biolog&#xed;a Molecular, Facultad de Biolog&#xed;a, Universidad Complutense, 28040 Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Lago</LastName><ForeName>Eva</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0002-6260-3777</Identifier><AffiliationInfo><Affiliation>Instituto Universitario de Investigaci&#xf3;n en Neuroqu&#xed;mica, Departamento de Bioqu&#xed;mica y Biolog&#xed;a Molecular, Facultad de Medicina, Universidad Complutense, 28040 Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red de Enfermedades Neurodegenerativas (CIBERNED), 28040 Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Instituto Ram&#xf3;n y Cajal de Investigaci&#xf3;n Sanitaria (IRYCIS), 28040 Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fern&#xe1;ndez-Ruiz</LastName><ForeName>Javier</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-4490-0604</Identifier><AffiliationInfo><Affiliation>Instituto Universitario de Investigaci&#xf3;n en Neuroqu&#xed;mica, Departamento de Bioqu&#xed;mica y Biolog&#xed;a Molecular, Facultad de Medicina, Universidad Complutense, 28040 Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red de Enfermedades Neurodegenerativas (CIBERNED), 28040 Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Instituto Ram&#xf3;n y Cajal de Investigaci&#xf3;n Sanitaria (IRYCIS), 28040 Madrid, Spain.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>CB06/05/0089 - CB/06/05/0005 - PI2018/01-1</GrantID><Agency>Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red sobre Enfermedades Neurodegenerativas</Agency><Country/></Grant><Grant><GrantID>RTI-2018-098885-B-100 and RTI-2018-095311-B-100</GrantID><Agency>Ministerio de Ciencia, Innovaci&#xf3;n y Universidades</Agency><Country/></Grant><Grant><GrantID>B2017/BMD-3813</GrantID><Agency>Programa de Biomedicina - Comunidad de Madrid</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>11</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Int J Mol Sci</MedlineTA><NlmUniqueID>101092791</NlmUniqueID><ISSNLinking>1422-0067</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000091342">Endoplasmic Reticulum Chaperone BiP</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000717248">Hspa5 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D043884">Receptor, Cannabinoid, CB1</NameOfSubstance></Chemical><Chemical><RegistryNumber>8HW4YBZ748</RegistryNumber><NameOfSubstance UI="D016627">Oxidopamine</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="C000606291">Sod1 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="D000072105">Superoxide Dismutase-1</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001253" MajorTopicYN="N">Astrocytes</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000091342" MajorTopicYN="N">Endoplasmic Reticulum Chaperone BiP</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005786" MajorTopicYN="N">Gene Expression Regulation</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009046" MajorTopicYN="N">Motor Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016627" MajorTopicYN="N">Oxidopamine</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D043884" MajorTopicYN="N">Receptor, Cannabinoid, CB1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013378" MajorTopicYN="N">Substantia Nigra</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000072105" MajorTopicYN="N">Superoxide Dismutase-1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">BiP interactor protein</Keyword><Keyword MajorTopicYN="N">BiP+/&#x2212; mice</Keyword><Keyword MajorTopicYN="N">CB1 receptors</Keyword><Keyword MajorTopicYN="N">Parkinson&#x2019;s disease</Keyword><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">cannabinoids</Keyword><Keyword MajorTopicYN="N">mSOD1 mice</Keyword><Keyword MajorTopicYN="N">spinal cord</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>6</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>11</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>11</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>11</Month><Day>27</Day><Hour>1</Hour><Minute>12</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>11</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>12</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34830414</ArticleId><ArticleId IdType="pmc">PMC8621319</ArticleId><ArticleId IdType="doi">10.3390/ijms222212533</ArticleId><ArticleId IdType="pii">ijms222212533</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Fern&#xe1;ndez-Ruiz J. The biomedical challenge of neurodegenerative disorders: An opportunity for cannabinoid-based ther-apies to improve on the poor current therapeutic outcomes. Br. J. Pharmacol. 2019;176:1370&#x2013;1383. doi: 10.1111/bph.14382.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bph.14382</ArticleId><ArticleId IdType="pmc">PMC6487558</ArticleId><ArticleId IdType="pubmed">29856067</ArticleId></ArticleIdList></Reference><Reference><Citation>Fern&#xe1;ndez-Ruiz J., Moro M.A., Martinez-Orgado J. Cannabinoids in Neurodegenerative Disorders and Stroke/Brain Trauma: From Preclinical Models to Clinical Applications. Neurotherapeutics. 2015;12:793&#x2013;806. doi: 10.1007/s13311-015-0381-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13311-015-0381-7</ArticleId><ArticleId IdType="pmc">PMC4604192</ArticleId><ArticleId IdType="pubmed">26260390</ArticleId></ArticleIdList></Reference><Reference><Citation>Aymerich M.S., Aso E., Abellanas M.A., Tolon R.M., Ramos J.A., Ferrer I., Romero J., Fern&#xe1;ndez-Ruiz J. Cannabinoid pharma-cology/therapeutics in chronic degenerative disorders affecting the central nervous system. Biochem. Pharmacol. 2018;157:67&#x2013;84. doi: 10.1016/j.bcp.2018.08.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bcp.2018.08.016</ArticleId><ArticleId IdType="pubmed">30121249</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiarlone A., Bellocchio L., Bl&#xe1;zquez C., Resel E., Soria-G&#xf3;mez E., Cannich A., Ferrero J.J., Sagredo O., Benito C., Romero J., et al. A restricted population of CB1 cannabinoid re-ceptors with neuroprotective activity. Proc. Natl. Acad. Sci. USA. 2014;111:8257&#x2013;8262. doi: 10.1073/pnas.1400988111.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1400988111</ArticleId><ArticleId IdType="pmc">PMC4050577</ArticleId><ArticleId IdType="pubmed">24843137</ArticleId></ArticleIdList></Reference><Reference><Citation>Hiebel C., Behl C. The complex modulation of lysosomal degradation pathways by cannabinoid receptors 1 and 2. Life Sci. 2015;138:3&#x2013;7. doi: 10.1016/j.lfs.2015.03.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lfs.2015.03.020</ArticleId><ArticleId IdType="pubmed">25908257</ArticleId></ArticleIdList></Reference><Reference><Citation>Aso E., Palomer E., Juv&#xe9;s S., Maldonado R., Mu&#xf1;oz F.J., Ferrer I. CB1 Agonist ACEA Protects Neurons and Reduces the Cognitive Impairment of A&#x3b2;PP/PS1 Mice. J. Alzheimer&#x2019;s Dis. 2012;30:439&#x2013;459. doi: 10.3233/JAD-2012-111862.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-2012-111862</ArticleId><ArticleId IdType="pubmed">22451318</ArticleId></ArticleIdList></Reference><Reference><Citation>Navarro G., Borroto-Escuela D., Angelats E., Etayo &#xcd;., Reyes-Resina I., Pulido-Salgado M., Rodr&#xed;guez-P&#xe9;rez A.I., Canela E.I., Saura J., Lanciego J.L., et al. Receptor-heteromer mediated regulation of endocan-nabinoid signaling in activated microglia. Role of CB1 and CB2 receptors and relevance for Alzheimer&#x2019;s disease and levo-dopa-induced dyskinesia. Brain Behav. Immun. 2018;67:139&#x2013;151. doi: 10.1016/j.bbi.2017.08.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbi.2017.08.015</ArticleId><ArticleId IdType="pubmed">28843453</ArticleId></ArticleIdList></Reference><Reference><Citation>Crunfli F., Vrechi T.A., Costa A.P., Torr&#xe3;o A.S. Cannabinoid Receptor Type 1 Agonist ACEA Improves Cognitive Deficit on STZ-Induced Neurotoxicity through Apoptosis pathway and NO Modulation. Neurotox. Res. 2019;35:516&#x2013;529. doi: 10.1007/s12640-018-9991-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12640-018-9991-2</ArticleId><ArticleId IdType="pubmed">30607903</ArticleId></ArticleIdList></Reference><Reference><Citation>Bl&#xe1;zquez C., Chiarlone A., Sagredo O., Aguado T., Pazos M.R., Resel E., Palazuelos J., Julien B., Salazar M., B&#xf6;rner C., et al. Loss of striatal type 1 cannabinoid receptors is a key pathogenic factor in Huntington&#x2019;s disease. Brain. 2011;134:119&#x2013;136. doi: 10.1093/brain/awq278.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awq278</ArticleId><ArticleId IdType="pubmed">20929960</ArticleId></ArticleIdList></Reference><Reference><Citation>Blazquez C., Chiarlone A., Bellocchio L., Resel E., Pruunsild P., Garc&#xed;a-Rinc&#xf3;n D., Sendtner M., Timmusk T., Lutz B., Galve-Roperh I., et al. The CB1 cannabinoid receptor signals striatal neuroprotection via a PI3K/Akt/mTORC1/BDNF pathway. Cell Death Differ. 2015;22:1618&#x2013;1629. doi: 10.1038/cdd.2015.11.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/cdd.2015.11</ArticleId><ArticleId IdType="pmc">PMC4563779</ArticleId><ArticleId IdType="pubmed">25698444</ArticleId></ArticleIdList></Reference><Reference><Citation>Maya-L&#xf3;pez M., Col&#xed;n-Gonz&#xe1;lez A.L., Aguilera G., De Lima M.E., Colpo-Ceolin A., Rangel-Lopez E., Villeda-Hern&#xe1;ndez J., Rembao-Boj&#xf3;rquez D., T&#xfa;nez I., Luna-L&#xf3;pez A., et al. Neuroprotective effect of WIN55,212-2 against 3-nitropropionic acid-induced toxicity in the rat brain: Involvement of CB1 and NMDA receptors. Am. J. Transl. Res. 2017;9:261&#x2013;274.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5340665</ArticleId><ArticleId IdType="pubmed">28337258</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruiz-Calvo A., Maroto I.B., Bajo-Gra&#xf1;eras R., Chiarlone A., Gaudioso A., Ferrero J.J., Resel E., S&#xe1;nchez-Prieto J., Rodr&#xed;guez-Navarro A.J., Marsicano G., et al. Pathway-Specific Control of Striatal Neuron Vulnerability by Corticostriatal Cannabinoid CB1 Receptors. Cereb. Cortex. 2018;28:307&#x2013;322. doi: 10.1093/cercor/bhx285.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cercor/bhx285</ArticleId><ArticleId IdType="pubmed">29121220</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossi S., Furlan R., De Chiara V., Muzio L., Musella A., Motta C., Studer V., Cavasinni F., Bernardi G., Martino G., et al. Cannabinoid CB1 receptors regulate neuronal TNF-&#x3b1; effects in experimental auto-immune encephalomyelitis. Brain Behav. Immun. 2011;25:1242&#x2013;1248. doi: 10.1016/j.bbi.2011.03.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbi.2011.03.017</ArticleId><ArticleId IdType="pubmed">21473912</ArticleId></ArticleIdList></Reference><Reference><Citation>Moreno-Martet M., Feli&#xfa; A., Espejo-Porras F., Mecha M., Carrillo-Salinas F.J., Fern&#xe1;ndez-Ruiz J., Guaza C., de Lago E. The disease-modifying effects of a Sativex-like combination of phytocannabinoids in mice with experimental autoimmune en-cephalomyelitis are preferentially due to &#x394;9-tetrahydrocannabinol acting through CB1 receptors. Mult. Scler. Relat. Disord. 2015;4:505&#x2013;511. doi: 10.1016/j.msard.2015.08.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.msard.2015.08.001</ArticleId><ArticleId IdType="pubmed">26590655</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung Y.C., Bok E., Huh S.H., Park J.Y., Yoon S.H., Kim S.R., Kim Y.S., Maeng S., Park S.H., Jin B.K. Cannabinoid receptor type 1 protects nigrostriatal dopaminergic neurons against MPTP neurotoxicity by inhibiting microglial activation. J. Immunol. 2011;187:6508&#x2013;6517. doi: 10.4049/jimmunol.1102435.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1102435</ArticleId><ArticleId IdType="pubmed">22079984</ArticleId></ArticleIdList></Reference><Reference><Citation>P&#xe9;rez-Rial S., Garc&#xed;a-Guti&#xe9;rrez M.S., Molina J.A., P&#xe9;rez-Nievas B.G., Ledent C., Leiva C., Leza J.C., Manzanares J. Increased vulnerability to 6-hydroxydopamine lesion and reduced development of dyskinesias in mice lacking CB1 cannabinoid receptors. Neurobiol. Aging. 2011;32:631&#x2013;645. doi: 10.1016/j.neurobiolaging.2009.03.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2009.03.017</ArticleId><ArticleId IdType="pubmed">19419794</ArticleId></ArticleIdList></Reference><Reference><Citation>Mart&#xed;nez-Pinilla E., Aguinaga D., Navarro G., Rico A.J., Oyarz&#xe1;bal J., S&#xe1;nchez-Arias J.A., Lanciego J.L., Franco R. Targeting CB1 and GPR55 Endocannabinoid Receptors as a Potential Neuroprotective Approach for Parkinson&#x2019;s Disease. Mol. Neurobiol. 2019;56:5900&#x2013;5910. doi: 10.1007/s12035-019-1495-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-019-1495-4</ArticleId><ArticleId IdType="pubmed">30687889</ArticleId></ArticleIdList></Reference><Reference><Citation>Abood M.E., Rizvi G., Sallapudi N., McAllister S.D. Activation of the CB1 cannabinoid receptor protects cultured mouse spinal neurons against excitotoxicity. Neurosci. Lett. 2001;309:197&#x2013;201. doi: 10.1016/S0304-3940(01)02065-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0304-3940(01)02065-1</ArticleId><ArticleId IdType="pubmed">11514075</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao P., Ignacio S., Beattie E.C., Abood M.E. Altered presymptomatic AMPA and cannabinoid receptor trafficking in motor neurons of ALS model mice: Implications for excitotoxicity. Eur. J. Neurosci. 2008;27:572&#x2013;579. doi: 10.1111/j.1460-9568.2008.06041.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1460-9568.2008.06041.x</ArticleId><ArticleId IdType="pmc">PMC3991137</ArticleId><ArticleId IdType="pubmed">18279310</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossi S., De Chiara V., Musella A., Cozzolino M., Bernardi G., Maccarrone M., Mercuri N.B., Carr&#xec; M.T., Centonze D. Abnormal sensitivity of cannabinoid CB1 receptors in the striatum of mice with experimental amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. 2019;11:83&#x2013;90. doi: 10.3109/17482960902977954.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/17482960902977954</ArticleId><ArticleId IdType="pubmed">19452308</ArticleId></ArticleIdList></Reference><Reference><Citation>Oliver E.E., Hughes E.K., Puckett M.K., Chen R., Lowther W.T., Howlett A.C. Cannabinoid Receptor Interacting Protein 1a (CRIP1a) in Health and Disease. Biomolecules. 2020;10:1609. doi: 10.3390/biom10121609.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biom10121609</ArticleId><ArticleId IdType="pmc">PMC7761089</ArticleId><ArticleId IdType="pubmed">33261012</ArticleId></ArticleIdList></Reference><Reference><Citation>Costas-Insua C., Moreno E., Maroto I.B., Ruiz-Calvo A., Bajo-Gra&#xf1;eras R., Mart&#xed;n-Guti&#xe9;rrez D., Diez-Alarcia R., Vilar&#xf3; M.T., Cort&#xe9;s R., Garc&#xed;a-Font N., et al. Identification of BiP as a CB1 Receptor-Interacting Protein That Fine-Tunes Cannabinoid Signaling in the Mouse Brain. J. Neurosci. 2021;41:7924&#x2013;7941. doi: 10.1523/JNEUROSCI.0821-21.2021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.0821-21.2021</ArticleId><ArticleId IdType="pmc">PMC8460140</ArticleId><ArticleId IdType="pubmed">34353897</ArticleId></ArticleIdList></Reference><Reference><Citation>Gorbatyuk M., Gorbatyuk O. Review: Retinal degeneration: Focus on the unfolded protein response. Mol. Vis. 2013;19:1985.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3782367</ArticleId><ArticleId IdType="pubmed">24068865</ArticleId></ArticleIdList></Reference><Reference><Citation>Casas C. GRP78 at the Centre of the Stage in Cancer and Neuroprotection. Front. Neurosci. 2017;11:177. doi: 10.3389/fnins.2017.00177.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2017.00177</ArticleId><ArticleId IdType="pmc">PMC5380735</ArticleId><ArticleId IdType="pubmed">28424579</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin H., Komita M., Aoe T. The Role of BiP Retrieval by the KDEL Receptor in the Early Secretory Pathway and its Effect on Protein Quality Control and Neurodegeneration. Front. Mol. Neurosci. 2017;10:222. doi: 10.3389/fnmol.2017.00222.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnmol.2017.00222</ArticleId><ArticleId IdType="pmc">PMC5511815</ArticleId><ArticleId IdType="pubmed">28769758</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo S., Mao C., Lee B., Lee A.S. GRP78/BiP is required for cell proliferation and protecting the inner cell mass from apoptosis during early mouse embryonic development. Mol. Cell Biol. 2006;26:5688&#x2013;5697. doi: 10.1128/MCB.00779-06.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/MCB.00779-06</ArticleId><ArticleId IdType="pmc">PMC1592753</ArticleId><ArticleId IdType="pubmed">16847323</ArticleId></ArticleIdList></Reference><Reference><Citation>Gorbatyuk M., Shabashvili A., Chen W., Meyers C., Sullivan L.F., Salganik M., Lin J.H., Lewin A., Muzyczka N., Gorbatyuk O.S. Glucose Regulated Protein 78 Diminishes &#x3b1;-Synuclein Neurotoxicity in a Rat Model of Parkinson Disease. Mol. Ther. 2012;20:1327&#x2013;1337. doi: 10.1038/mt.2012.28.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mt.2012.28</ArticleId><ArticleId IdType="pmc">PMC3392977</ArticleId><ArticleId IdType="pubmed">22434142</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeon G.S., Shim Y.-M., Lee D.-Y., Kim J.-S., Kang M., Ahn S.H., Shin J.-Y., Geum D., Hong Y.-H., Sung J.-J. Pathological Modification of TDP-43 in Amyotrophic Lateral Sclerosis with SOD1 Mutations. Mol. Neurobiol. 2019;56:2007&#x2013;2021. doi: 10.1007/s12035-018-1218-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-018-1218-2</ArticleId><ArticleId IdType="pmc">PMC6394608</ArticleId><ArticleId IdType="pubmed">29982983</ArticleId></ArticleIdList></Reference><Reference><Citation>Cueto C.R., Santos-Garc&#xed;a I., Garc&#xed;a-Toscano L., Espejo-Porras F., Bellido M., Fern&#xe1;ndez-Ruiz J., Munoz E., de Lago E. Neuroprotective effects of the cannabigerol quinone derivative VCE-003.2 in SOD1G93A transgenic mice, an experimental model of amyotrophic lateral sclerosis. Biochem. Pharmacol. 2018;157:217&#x2013;226. doi: 10.1016/j.bcp.2018.07.049.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bcp.2018.07.049</ArticleId><ArticleId IdType="pubmed">30076846</ArticleId></ArticleIdList></Reference><Reference><Citation>Garc&#xed;a C., Palomo-Garo C., Garc&#xed;a-Arencibia M., Ramos J., Pertwee R., Fern&#xe1;ndez-Ruiz J. Symptom-relieving and neuroprotective effects of the phytocannabinoid &#x394;9-THCV in animal models of Parkinson&#x2019;s disease. Br. J. Pharmacol. 2011;163:1495&#x2013;1506. doi: 10.1111/j.1476-5381.2011.01278.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1476-5381.2011.01278.x</ArticleId><ArticleId IdType="pmc">PMC3165958</ArticleId><ArticleId IdType="pubmed">21323909</ArticleId></ArticleIdList></Reference><Reference><Citation>Alvarez-Fischer D., Henze C., Strenzke C., Westrich J., Ferger B., H&#xf6;glinger G.U., Oertel W.H., Hartmann A. Characterization of the striatal 6-OHDA model of Parkinson&#x2019;s disease in wild type and alpha-synuclein-deleted mice. Exp. Neurol. 2008;210:182&#x2013;193. doi: 10.1016/j.expneurol.2007.10.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2007.10.012</ArticleId><ArticleId IdType="pubmed">18053987</ArticleId></ArticleIdList></Reference><Reference><Citation>Fleming S.M., Ekhator O.R., Ghisays V. Assessment of sensorimotor function in mouse models of Parkinson&#x2019;s disease. J. Vis. Exp. 2013;76:50303. doi: 10.3791/50303.</Citation><ArticleIdList><ArticleId IdType="doi">10.3791/50303</ArticleId><ArticleId IdType="pmc">PMC3727502</ArticleId><ArticleId IdType="pubmed">23851663</ArticleId></ArticleIdList></Reference><Reference><Citation>Alvarez F.J., Lafuente H., Rey-Santano M.C., Mielgo E.V., Gastiasoro E., Rueda M., Pertwee R.G., Castillo I.A., Romero J., Mart&#xed;nez-Orgado J. Neuroprotective Effects of the Nonpsychoactive Cannabinoid Cannabidiol in Hypoxic-Ischemic Newborn Piglets. Pediatr. Res. 2008;64:653&#x2013;658. doi: 10.1203/PDR.0b013e318186e5dd.</Citation><ArticleIdList><ArticleId IdType="doi">10.1203/PDR.0b013e318186e5dd</ArticleId><ArticleId IdType="pubmed">18679164</ArticleId></ArticleIdList></Reference><Reference><Citation>Cepri&#xe1;n M., Jim&#xe9;nez-S&#xe1;nchez L., Vargas C., Barata L., Hind W., Mart&#xed;nez-Orgado J. Cannabidiol reduces brain damage and improves functional recovery in a neonatal rat model of arterial ischemic stroke. Neuropharmacology. 2017;116:151&#x2013;159. doi: 10.1016/j.neuropharm.2016.12.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuropharm.2016.12.017</ArticleId><ArticleId IdType="pubmed">28012949</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>